Table 1.

Clinical trials of orexin receptor antagonists for the treatment of substance abuse disorders

Title of trial	Status	Conditions	ClinicalTrials.gov Identifier
Medication Development in Alcoholism: Suvorexant versus Placebo	Not yet recruiting	Alcohol use disorder	NCT04229095
Suvorexant in the Management Comorbid Sleep Disorder and Alcohol Dependence	Recruiting	Alcohol use disorder	NCT03897062
Suvorexant and Cocaine	Recruiting	Cocaine use disorder	NCT03937986
Role of the Orexin Receptor System in Stress, Sleep and Cocaine Use	Completed	Cocaine use disorder/Anxiety	NCT02785406
Medical Management of Sleep Disturbance During Opioid Tapering	Recruiting	Opioid use disorder	NCT03789214
Examining the Role of the Orexin System in Sleep and Stress in Persons with Opioid Use Disorder	Recruiting	Opioid use disorder	NCT04287062
Dual-Orexin Antagonism as a Mechanism for Improving Sleep and Drug Abstinence in Opioid Use Disorder	Recruiting	Opioid use disorder	NCT04262193
The Efficacy of Suvorexant in Treatment of Patients with Substance Use Disorder and Insomnia: A Pilot Open Trial	Enrolling by invitation	Opioid use disorder Alcohol use disorder	NCT03412591
Suvorexant to Reduce Symptoms of Nicotine Use	Not yet recruiting	Nicotine dependence	NCT04234997
Targeting Orexin to Treat Nicotine Dependence	Recruiting	Nicotine dependence	NCT03999099

A ClinicalTrials.gov search (accessed on Jan 1, 2021) yielded ten trials of orexin system modulators for substance use disorders at different stages of progress in the US and Australia, as listed here.